Merck & Co (MRK)
85.99
+0.00 (0.00%)
NYSE · Last Trade: Oct 13th, 8:07 AM EDT
Now may be the time to invest in drug companies, as they just slipped the tariff noose.
Via The Motley Fool · October 13, 2025
Global financial markets are currently experiencing a significant divergence, with Asian shares facing considerable pressure due to escalating US-China trade tensions, while Wall Street futures have staged a notable rebound. This split reaction, observed around October 12, 2025, highlights the immediate and often contrasting interpretations of heightened geopolitical risks and
Via MarketMinute · October 12, 2025
Washington D.C., October 10, 2025 – The financial markets are bracing for impact as the September 2025 Consumer Price Index (CPI) report looms, a critical piece of economic data that promises to shine a harsh light on persistent inflation. This report, due for release amidst an ongoing government shutdown, is
Via MarketMinute · October 10, 2025
UK ministers consider raising NHS drug spending by up to 25% amid pharma investment delays and pressure from US pricing policies.
Via Benzinga · October 10, 2025
New York, NY – October 9, 2025 – Pfizer Inc. (NYSE:PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of 2025. This latest payout marks a significant milestone: the company's 348th consecutive quarterly dividend. The unwavering consistency of
Via MarketMinute · October 9, 2025
Parsippany, N.J. – October 9, 2025 – Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today declared a quarterly dividend of $0.50 per share for the fourth quarter of 2025. This proactive announcement, made well in advance of the payment date, underscores the company's consistent commitment to shareholder
Via MarketMinute · October 9, 2025
NEW YORK, NY – October 9, 2025 – Zoetis Inc. (NYSE:ZTS), the world's leading animal health company, today announced a quarterly dividend of $0.50 per share for the fourth quarter of 2025. This declaration, made on the current date of October 9, 2025, underscores the company's consistent commitment to shareholder
Via MarketMinute · October 9, 2025
New York, NY – October 9, 2025 – Pfizer Inc. (NYSE: PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of 2025. This payment marks a significant milestone as the company's 348th consecutive quarterly dividend, a testament to its
Via MarketMinute · October 9, 2025
After years of lagging, the healthcare sector is showing signs of a turnaround driven by lower rates, policy clarity, and renewed investor interest.
Via MarketBeat · October 9, 2025
Merck and health experts push back against U.S. officials' call to split the MMR vaccine, warning it could delay immunizations and weaken immune response.
Via Benzinga · October 7, 2025
Shares climbed Tuesday as enthusiasm grows for the biotech company's experimental cancer drug.
Via Investor's Business Daily · October 7, 2025
This biotech company was relatively unknown a few years ago.
Via The Motley Fool · October 5, 2025
S&P500, Nasdaq100, Dow Jones, and Russell 2000 all hit record highs as investors focus on corporate optimism, monetary easing and AI tech.
Via Benzinga · October 3, 2025
Via Benzinga · October 3, 2025
Washington D.C., October 2, 2025 – As a federal government shutdown extends into its second day, the highly anticipated U.S. Jobs Report, typically released on the first Friday of each month, has been delayed indefinitely. This immediate consequence of the government's funding lapse creates a significant blind spot for
Via MarketMinute · October 2, 2025
Health care stocks are rallying, but Pfizer, Merck and Bristol-Myers still trade below 10x forward P/E — a rare market discount.
Via Benzinga · October 2, 2025
Worried about sliding interest on your savings? These three Dow stocks are yielding more than 4%.
Via The Motley Fool · October 2, 2025
Paris, France – October 2, 2025 – Nanobiotix (NASDAQ: NBTX) witnessed a significant surge in its stock price today, jumping 11.6%, following the announcement of highly encouraging initial data from a Phase 1 study of its lead product, JNJ-1900 (NBTXR3), in patients with locally advanced esophageal adenocarcinoma. This pivotal development, revealed
Via MarketMinute · October 2, 2025
London, UK – October 2, 2025 – In a monumental stride for biotechnology and medicine, generative artificial intelligence (AI) has achieved a scientific breakthrough, demonstrating an unprecedented ability to design synthetic proteins for genome editing that not only match but significantly outperform their naturally occurring counterparts. This pivotal development, highlighted by recent research, signals a [...]
Via TokenRing AI · October 2, 2025
Stocks shrugged off Washington’s chaos as hopes for Fed rate cuts and strong corporate news kept investors in a buying mood.
Via Chartmill · October 2, 2025
Shares of global pharmaceutical company Merck (NYSE:MRK)
jumped 7.7% in the afternoon session after the Trump administration announced a new program to sell drugs directly to consumers.
Via StockStory · October 1, 2025
Health care stocks rallied after Trump struck a drug pricing deal with Pfizer, offering major discounts and pausing pharma tariffs.
Via Benzinga · October 1, 2025
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday.
Via Chartmill · October 1, 2025
In today's session, there are S&P500 stocks with remarkable trading volume. Explore the stocks exhibiting unusual volume in Wednesday's session.
Via Chartmill · October 1, 2025